Navigation Links
Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
Date:5/31/2011

EAST HANOVER, N.J., June 1, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") will showcase data from 140 abstracts on its current oncology products and investigational agents at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). These data underscore the company's commitment to developing treatments to improve the lives of patients with cancer.

"Through our commitment to R&D and collaborations with the scientific and patient communities, we continue to bring targeted treatments to patients living with cancer and other diseases for which there is an unmet need," said Hervé Hoppenot, President, Novartis Oncology. "Our broad and deep portfolio of development programs gives us multiple opportunities to further advance treatments for the millions of patients and their families affected by these diseases."

Highlighted at the ASCO meeting, taking place from June 3 - 7 in Chicago, will be results from key Phase III studies on Novartis products and compounds, including a trial on adjuvant treatment with Gleevec® (imatinib mesylate) tablets* in patients following resection of KIT (CD117)-positive gastrointestinal stromal tumors (GIST) featured at the plenary session on June 5, and two pivotal studies of the Janus kinase (JAK) inhibitor, INC424 (ruxolitinib), in patients with myelofibrosis on June 6(1). In addition, a study of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), showing patients on Tasigna® (nilotinib) 150 mg capsules are less likely to develop mutations than those taking Gleevec, will be presented on June 6(1).

Also featured at the Annual Congress will be results from two sub-analyses of the landmark Medical Research Council Myeloma IX clinical trial comparing the effect of Zometa® (zoledronic acid) Injection versus clodronate, on overall survival, progression-free survival and skeletal-related events when used with
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... -- The potential of the pulmonary route ... agents has been receiving undeniable attention with the recent ... The crucial formulation considerations for orally inhaled products together ... role in the efficiency of pulmonary delivery, and great ... formulation techniques and devices in recent years. ...
(Date:5/23/2013)... PARÍS, 24 de mayo de 2013  Volcano ... desarrollador y fabricante de herramientas de precisión para ... tratamiento de la enfermedad vascular periférica y coronaria, ... ( Ad enosine V asodilator I ... durante la sesión de ensayo clínico hot line ...
(Date:5/23/2013)... Nephros, Inc. (OTC Bulletin Board: ... develops and sells high performance liquid purification ultrafilters, announced ... addition, the concurrent temporary reduction in exercise price for ... 2013. Nephros estimates that it will receive ... A portion of the proceeds will be used for ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... 18, 2012 UCB, Inc., a leading biopharmaceutical company ... severe central nervous system and immunological disorders, is marking ... reinforcing its commitment to improving the lives of patients ... this year,s DDW meeting. "DDW is ...
... The new arthroscopy simulator ArthroS trains orthopedic surgeons for ... The Swiss company VirtaMed AG is launching ArthroS™, a ... get the chance to practice different operations numerous times ... as pilots improve their skills on flight simulators. ArthroS™ ...
Cached Medicine Technology:UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 2UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 3UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 4Swiss Engineering for Surgical Perfection 2Swiss Engineering for Surgical Perfection 3
(Date:5/25/2013)... York (PRWEB) May 25, 2013 Pradaxa ... suffered serious, life-threatening episodes of internal bleeding while using the ... in U.S. District Court, Southern District of Illinois, Bernstein Liebhard ... website, 818 Pradaxa side effect claims had been ... That’s up from 705 claims reported by the Court on ...
(Date:5/25/2013)... York, NY (PRWEB) May 25, 2013 ... dedicated to brain cancer research and advocacy, comments on ... Extraterrestrial Physics, that shows incorporating cold atmospheric plasma into ... cells. , According to a Science Daily ... Extraterrestrial Physics (MPE), biologists and physicians demonstrated the “synergistic ...
(Date:5/25/2013)... 25, 2013 Dr. Farooq Ashraf, founder ... in Dubai, has announced his practice’s adoption of The ... only FDA-cleared femtosecond laser proven with more than 10 ... precision of LASIK. , “We are happy to announce ... Laser at our Dubai LASIK practice,” Ashraf said Thursday. ...
(Date:5/25/2013)... 2013 The Slim Weight Patch has been ... This is due to the highly sought after ingredients that ... patch offers an extra 2 months supply & premium membership ... get the body you desire faster than ever. , ... , With Slim weight patch consumers can observe instant results ...
(Date:5/25/2013)... Texas (PRWEB) May 25, 2013 ... stressful than finals week. Increasingly, they are turning ... stay awake and study. For more on this, ... a drug treatment facility, warns that students who ... finals” are at risk for developing a physical ...
Breaking Medicine News(10 mins):Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Slim Weight Patch Advanced Weight Loss System Offers Extra Two Month Supply and Membership for Maximum Weight Loss 2Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2
... (NYSE: SCI ) announced it expects to issue a press release ... 2009, after the market closes. A conference call will be hosted ... conference call are as follows: , , ... Conference Call, ...
... ... , ... 2, 2009 -- Life Care Centers of America recently named Michael Lops as ... Life Care, succeeds Sharon Coleman in the position. His appointment is based on “his extensive ...
... visit questionnaire led to screening in high-risk study patients ... questionnaire can identify patients at high risk for lung ... in 2001 with 1,000 people in Colorado who were ... patients were asked to complete a five-minute questionnaire that ...
... ... become a certifying body upon the release of the Office of the National Coordinator for ... Group has been approached recently by numerous EHR software and services companies that need to ... Fort Worth, ...
... Nov. 2 What do sipping cocoa, snuggling under blankets ... more common during the cold winter months. , According ... 1,200 Americans die annually from a heart attack or similar ... is often the trigger. To help create awareness, work to ...
... 2 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies,Inc. (the "Company") (Nasdaq: ... develops, manufactures and markets advanced in-vitro diagnostic,products, today announced ... second fiscal quarter ended September 30, 2009 ("2Q FY2009") ... The Company,s 2009 fiscal year,ends on March 31, 2010. ...
Cached Medicine News:Health News:Service Corporation International Announces Schedule for Its Third Quarter 2009 Earnings Release and Conference Call 2Health News:Lops named Life Care's New Chief Compliance Officer 2Health News:Drummond Group Plans to Certify Electronic Health Records 2Health News:Drummond Group Plans to Certify Electronic Health Records 3Health News:MTD Joins Forces with the AHA to Promote Heart Health 2Health News:China Medical Technologies to Announce Unaudited Financial Results for the Second Fiscal Quarter Ended September 30, 2009 on November 19, 2009 2
... a new standard in QPCR with the ... system offers superior performance, more flexibility, and ... system - with Windows 98SE and Pentium ... Premier Sound Speakers, Surge Protector (US only), ...
... The LightCycler System is the ... The LightCycler System enables you to ... 30 min, and simultaneously quantify and ... during amplification. The unique Melting Curve ...
... ABI PRISM 7900HT Sequence Detection System ... that detects and quantitates nucleic acid ... 384-well plate capability make the 7900HT ... high-throughput requirements of todays drug discovery ...
Sealing Mat for 96-well, 2.0ml, Deep Well, Square Available Sterile...
Medicine Products: